ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MREO

Group 1 - The Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc (NASDAQ: MREO) about the April 6, 2026 lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Mereo ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][7] Group 2 - The lawsuit alleges that Mereo BioPharma provided misleading information regarding the expected results of the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI) [5] - Defendants are accused of making positive statements about setrusumab's efficacy while concealing adverse facts about the Phase 3 programs, which did not meet their primary endpoints [6] - The misleading statements led to investors purchasing Mereo's ADSs at inflated prices, resulting in damages when the true information became public [6]